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2Abstract
Background:	Recently,	continuous	administration	of	piperacillin-tazobactam	has	been	proposed	as	a
valuable	alternative	to	traditional	intermittent	administration	especially	in	critically	ill	patients.
However,	antibiotic	dosing	remains	a	challenge	for	clinicians	as	antibiotic	dosing	regimens	are	usually
determined	in	non-critically-ill	hospitalized	adult	patients.	The	aim	was	to	conduct	a	systematic
review	to	identify	and	highlight	studies	comparing	clinical	outcomes	of	piperacillin	tazobactam	dosing
regimens,	continuous/prolonged	infusion	vs	intermittent	infusion	in	critically	ill	patients.	Meta-
analyses	were	performed	to	assess	the	overall	effect	of	dosing	regimen	on	clinical	efficacy.
Methods:	Studies	were	identified	systematically	through	searches	of	PubMed	and	Science	Direct,	in
compliance	with	PRISMA	guidelines.	Following	the	systematic	literature	review,	meta-analyses	were
performed	using	Review	Manager.
Results:	Twenty-three	studies	were	included	in	the	analysis	involving	3828	critically	ill	adult
participants	in	total	(continuous/prolonged	infusion	=	2197	and	intermittent	infusion	=	1631)	from
geographically	diverse	regions.	Continuous/prolonged	resulted	in	significantly:	higher	clinical	cure
rates	(OR	1.56,	95%	C.I	1.28-1.90,	P	=	0	.0001),	lower	mortality	rates	(OR	0.68,	95%	C.I	0.55-0.84,	P
=	0	.0003),	higher	microbiological	success	rates	(OR	1.52,	95%	C.I	1.10-2.11,	P	=	0.01)	and
decreasing	the	length	of	hospital	stay	(OR	-1.27,	95%	C.I	-2.45—0.08,	P	=	0.04)	in	critically	ill
patients.
Conclusion:	There	is	a	significant	level	of	evidence	that	clinical	outcome	in	critically	ill	patients	is
improved	in	patients	receiving	piperacillin-tazobactam	via	continuous/prolonged	infusion.	Therefore,
this	alternative	infusion	strategy	could	be	recommended	in	clinical	practice.
1	Introduction
Recently,	continuous	administration	of	piperacillin-tazobactam	has	been	proposed	as	a	valuable
alternative	to	traditional	intermittent	administration	especially	in	critically	ill	patients.	However,
correct	antibiotic	dosing	remains	a	challenge	for	clinicians	as	antibiotic	dosing	regimens	are	usually
determined	in	non-critically-ill	hospitalized	adult	patients.	Patient	that	are	in	intensive	care	units	(ICU)
differ	from	other	hospitalized	patients	in	terms	of	pathophysiology	and	disease	severity;	these	factors
3not	only	affect	metabolism	but	also	drug	pharmacokinetics/pharmacodynamics	(PK/PD)	behaviour.
Critically	ill	patients	also	have	an	increased	risk	(5–10	times	more	likely)	of	having	or	developing
infections	and	infectious	complications	than	those	in	general	wards	(1).
Dosing	strategies	that	have	been	validated	in	patient	populations	that	are	non-critically	ill	fail	to
consider	the	substantial	changes	in	organ	function	that	occur	with	critical	illness	(2).	Augmented	renal
clearance	of	antibiotics	is	increasingly	reported	in	critically	ill	patients.	Antibiotic	dosing
concentrations	will	vary	greatly	within	intensive	care	patients	with	normal	kidney	function	or	renal
failure	as	the	pharmacokinetic	target	attainment	is	dependent	on	kidney	function	(3).	Given	the
enhanced	renal	elimination	reported	in	critically	ill	patients,	antimicrobial	dosing	requires	extensive
consideration	due	to	important	clinical	consequences	as	accurate	and	timely	drug	exposure	is
essential	for	clinical	success.	The	augmented	renal	clearance	is	possibly	associated	with	the	(1)
immune	response	to	infection,	(2)	inflammation	to	fluid	loading	and,	(3)	use	of	vasoactive
medications.	An	increase	in	both	cardiac	output	and	blood	flow	is	therefore	observed,	leading	to
enhanced	glomerular	filtration	that	results	in	sub-therapeutic	piperacillin-tazobactam	concentrations
due	to	substantial	drug	elimination	(4).
The	optimisation	of	antimicrobial	agents	is	a	relatively	unexplored	area	where	further	research	is
needed.	Continuous	infusions	(CI)	and	prolonged	infusions	(PI)	of	piperacillin-tazobactam	has	been
directly	linked	to	improved	clinical	outcome	displaying	capabilities	such	as	lowering	the	possibility	of
resistance	and	decreasing	mortality	(2,5,6).	The	aim	here	is	to	systematically	review	the	literature
comparing	the	clinical	outcome	of	piperacillin	tazobactam	dosing	regimens,	continuous/prolonged
infusion	C/PI	and	II.
2	Methods
Literature	Search
A	systematic	review	of	the	literature	was	conducted	(7–10);	references	published	between	1998	and
2019	were	acknowledged	through	searches	on	PubMed	and	Science	Direct,	in	compliance	with
PRISMA	guidelines.	Search	terms	used	were:	(penicillin	OR	penicillins	OR	piperacillin	OR	tazobactam
OR	piperacillin-tazobactam	OR	piperacillin/tazobactam)	AND	(intermittent	OR	bolus	OR	short	OR
4prolonged	OR	extended	OR	continuous)	AND	(infusion	OR	duration	OR	administration	OR	interval	OR
dosing)	AND	(intensive	care	OR	ICU	OR	critically	ill	OR	critical	care	OR	septic	shock	OR	sepsis	OR
severe	sepsis).
However,	like	any	database,	their	coverage	is	not	complete,	therefore	the	authors	retrieved	additional
articles	using	supplementary	approaches	such	as	manual	searching	of	journals,	Google	Scholar	and
checking	reference	lists	of	articles	to	identify	additional	text.	A	full	review	of	published	studies	was
implemented	addressing	and	comparing	clinical	outcome	of	IV	piperacillin-tazobactam	dosing
regimens	administered	to	infected	critically	ill	patients.	The	last	search	was	on	the	1st	of	August	2019
[PROSPERO	registration	number:	CRD42019117303].
Study	Selection
Initially,	all	articles	reporting	comparative	outcomes	of	critically	ill	patients	treated	with	C/PI	versus	II
piperacillin-tazobactam	were	considered	eligible.	The	eligibility	criteria	were	separated	into	two
components:	study	characteristics	and	report	characteristics.	Study	eligibility	criteria	included	the
types	of	a)	studies,	b)	participants,	c)	interventions	and	d)	outcome	measures;	these	measures	are
presented	in	Table.1.	Report	eligibility	criteria	included:	publications	written	in	English	language,
study	status	is	‘’published’’	and	inclusion	of	both	old	and	new	data.	Exclusion	criteria	included:
Pharmacoeconomic	studies,	non-human	subjects,	non-adult	subjects,	non-critically	ill	subjects,	non-
English	language	studies	and	pilot	studies.	Systematic	reviews,	meta-analysis	and	editorials	were	also
excluded.
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Showing	eligibility	criteria	for	study	selection	process
Eligibility	Criteria
a)	Studies Prospective	and	retrospective	trials/studiescomparing/evaluating	clinical	efficacy	or	clinicaloutcome	of	piperacillin/tazobactam	administeredvia	CI	vs	II	in	critically	ill	patients.	Pilot	studiesexcluded
b)	Participants Critically	ill	adult	participants	aged	19	and	oversuffering	from	documented	bacterial	infection	andrequiring	treatment	with	piperacillin-tazobactam.Non-adult,	non-human	and	non-critically	ill	patientstudies	were	excluded.
c)	Interventions Studies	comparing	the	beneficial	andharmful/limiting	effects	of	CI	and	II.	Infusions	of	alltypes	(CI,	PI	and	II),	dose	and	regimen	areadequate	for	the	review.	Pharmacoeconomicstudies	were	also	excluded.
d)	Outcome	measures All	studies	were	eligible	if	specifically	related	toclinical	outcome/efficacy	of	dosing	regimens.	Alloutcomes	were	included	to	reduce	risk	of	bias	as	aconsequence	of	selective	reporting.
CI = continuous	infusion;	II = intermittent	infusion
Data	Analysis
A	data	extraction	form	was	developed	based	on	Cochrane	data	extraction	template.	The	information
extracted	from	each	of	the	included	studies	consisted	of:
1.	 Characteristics	of	participants	(didn’t	necessarily	comprise	characteristics	such	as
age	and	sex	however,	includes	characteristics	such	as	the	disease	patient	is
diagnosed	with	and	the	method	of	diagnosis)	and	the	eligibility	criteria	(inclusion	and
exclusion	measures);
2.	 The	type	of	intervention	–	mode	of	administration,	continuous	vs	intermittent	dosing
(including	the	drug,	dose,	duration	of	infusion	and	frequency);
3.	 Type	of	outcome	measure	(including	clinical	outcome	and	clinical	efficacy	in	terms	of
clinical	cure).
One	reviewer	extracted	the	following	data	from	included	studies	(S.F);	the	second	and	third	reviewers
checked	the	extracted	information	(S.N-G	and	S.B).	Variances	in	opinions	were	resolved	by	discussion
between	the	three	reviewers.
Risk	of	Bias	and	Study	Quality	Assessment
Methodological	assessment	of	included	RCTs	was	undertaken	using	the	Cochrane	risk	of	bias	tool.
	Two	reviewers	individually	assessed	the	risk	of	bias	(S.F	and	S.N-G)	with	disagreements	resolved	by	a
6third	reviewer	(S.B).	Six	domains	of	bias	were	assessed	including:	(1)	random	sequence	generation,
(2)	allocation	concealment,	(3)	blinding	of	participants	and	personnel,	(4)	incomplete	outcome	data,
(5)	selective	reporting	and	(6)	other	biases.	Publication	bias	was	evaluated	using	funnel	plots.
The	methodological	quality	of	included	RCT’s	was	assessed	with	the	Jadad	Scale	(11)	that	evaluated
the	trial’s	randomisation,	double	blinding	and	reports	of	withdrawals	and	dropouts.	An	overall	score	of
0-5	points	was	assigned,	where	an	overall	score	of	three	and	above	was	regarded	as	adequate	trial
quality.
The	Newcastle-Ottawa	Scale	is	a	quality	assessment	tool	for	selection,	comparability	and	outcome
assessment	used	to	assess	the	quality	of	included	observational	studies	(retrospective	and
prospective)	(12).	Studies	scoring	more	than	six	stars	are	considered	as	being	good	quality.
No	studies	were	excluded	on	the	basis	of	quality	assessment	however	their	quality	scores	were	taken
into	account	when	describing	results.
Statistical	Analysis
Meta-analysis	was	performed	using	Review	Manager	for	Windows	Version	5.3	to	compare	the	clinical
efficacy	of	C/PI	vs	II	in	terms	of	clinical	cure,	mortality,	microbiological	cure	rates,	adverse	events	and
length	of	hospital	stay.	Pooled	odds	ratio	(OR)	and	95%	confidence	intervals	(C.I)	were	calculated	for
dichotomous	data,	taking	into	account	all	outcomes	from	included	studies.	Pooled	mean	difference
(MD)	and	95%	C.I	were	calculated	for	continuous	data.	Statistical	heterogeneity	was	assessed	by
employing	χ2	test	and	I2	statistic.	The	presence	of	heterogeneity	between	studies	was	assessed	by	χ2
test	(P	<	0.10	indicates	significant	heterogeneity)	and	the	extent	of	the	inconsistencies	was
considered	using	I2	statistic	(I2	>	70%	indicates	considerable	heterogeneity).	The	pooled	outcomes
were	calculated	using	Mantel-Haenszel	fixed	effect	model	when	there	was	no	significant
heterogeneity	otherwise	the	random	effects	model	was	chosen.	‘Emergence	of	resistance’	was
narratively	reviewed	instead	of	statistical	analysis	considering	the	few	sample	sizes	included.
3	Results
Search	Results
The	search	of	PubMed	and	Science	Direct	provided	199	citations.	Of	these,	154	studies	were	excluded
7following	review	of	the	abstracts,	as	they	did	not	meet	the	inclusion	criteria.	Twenty	articles	were
discarded	after	reviewing	the	full	article	due	to	the	following	reasons:	non-human	(n = 2),	on	non-
critically	ill	(n = 10)	and	children	(n = 8)	subjects.	A	further	four	studies	were	eliminated	due	to	the
focus	being	on	pharmacoeconomics	and	renal	replacement	therapy.
An	additional	two	studies	that	met	the	inclusion	criteria	were	acknowledged	through	checking
references	of	relevant	studies.	Twenty-three	studies	met	the	described	inclusion	criteria	and	were
included	in	the	systematic	review	(13,14,23–32,15,33,34,16–22).	The	article	selection	process	is
illustrated	in	Figure.1	and	selected	studies	comparing	clinical	outcome	between	CI	and	II	of
piperacillin	are	listed	in	Table.2.	Characteristics	of	included	studies	comprising	of	demographic
characteristics,	C/PI	and	II	dosage,	drug	regimen	treatment	results	as	well	as	study	outcomes	and
suggestions	were	extracted	from	all	studies	and	summarised	(Table	2).	Out	of	the	twenty-three
studies	included,	only	an	abstract	(and	no	full	article)	could	be	obtained	for	four	of	the	studies
(19,20,25,26).
Definitions
‘Clinical	cure’	was	defined	as	‘the	complete	resolution	of	clinical	signs	and	symptoms	of	infection,
with	no	new	signs	or	symptoms	associated	with	the	original	infection’.
‘Microbiological	cure’	was	defined	as	‘the	eradication	and	presumed	eradication	of	organisms	at	the
infection	site’.
‘Adverse	events’	were	defined	as	‘any	unexpected	medical	occurrences	in	patients	administered
piperacillin-tazobactam	caused	by	either	the	drug	or	dosing	regimen	being	received’.
Study	Characteristics
The	type	of	studies	included	in	the	systematic	review	and	meta-analysis	were	RCT’s	(n = 10),
observational	cohort	studies	(n = 12;	retrospective	n = 10,	prospective	n = 2)	and	a	Quasi-
experimental	study	(non-randomised	trial)	(n = 1).
Table	2
Characteristics	of	studies	comparing	outcomes	for	continuous	versus	intermittent	infusions	of
Piperacillin
Study Study
Design/Patient
Dosage Clinical	Cure	n/N
(%)
mORTALITY	N/N
(%)
Outcome/Suggestions
8Population
Grants	et	al.
2002	(13)
USA
Prospectivecohort	study98	Hospitalizedpatients
CI	(n = 47)	–	2	gLD + 8	g	DD	over24	h	CIII	(n = 51)	–	3	gevery	6	h	over30	min	II
CI-	44/47	(94%)II-	42/51	(82%) CI-	1/47	(2.1%)II-	5/51	(9.8%) CI	providedequivalentclinical	andmicrobiologic	toII.	CI	is	a	costeffectivealternative	to	II.CI	is	welltoleratedresulting	in	CC.
Lau	et	al.	2006
(14)
USA
Randomisedcontrol	trial167	patientswith	gram	(+)/(-)bacteria
CI	(n = 81)	–13.5	g	over	24	hCIII	(n = 86)	− 3.375	g	every6hrs	over	30	minII
CI-	70/81	(86%)II-	76/86	(88%) CI-	1/130	(0.8%)II-	3/132	(2.3%) CI	are	a	sameand	reasonablealternate	modeofadministration.No	differences	inbacteriologicalresponse	bypathogen	wasnoted	betweenCI	and	II.
Rafati	et	al.	2006
(15)
iran
Randomisedcontrol	trial40	Septic,critically	illpatients
CI	(n = 20)	–	2	gLD + 8	g	DD	over24	h	CIII	(n = 20)	–	3	gevery	6	h	over30	min	II
CI-	15/20	(75%)II-	16/20	(70%) CI-	5/20	(25%)II-	6/20	(30%) Clinical	efficacyas	a	CI	issuperior	to	thatwith	II.	CIsignificantlyreduces	severityof	illnessresulting	inclinical	cure.
Lodise	et	al.
2007	(16)
usa
Retrospectivecohort	Study194	ICU	patientswith	Pa
PI	(n = 102)	–3.375	g	every8hrs	over	4hr	PIII	(n = 92)	− 3.375	g	every	4-6hrs	over	30	minII
PI-	not	recordedII-	not	recorded PI-	5/41	(12.2%)II-12/92	(13%) No	difference	inbaseline	clinicalcharacteristicswere	notedbetween	the	twodosing	regimens,however,mortality	ratesweresignificantlylower	with	PI.
Roberts	et	al.
2009	(17)
Austrailia
Randomisedcontrol	trial16	Critically	illadult	patients
CI	(n = 8)	–	4	gLD + 8	g	DD	over24	h	CIII	(n = 8)	–	4	gevery	6–8	h	over20	min	II
CI-	8/8	(100%)II-	8/8	(100%) CI-	0/8	(0%)II-	0/8	(0%) Administrationby	CI	with	initialloading	doseachievessuperior	PDtarget	and	CCwhen	comparedwithconventional	II
Lorente	et	al.
2009	(18)
spain
Retrospectivecohort	study83	ICU	patientssuffering	VAP
CI	(n = 37)	− 4	gLD + 16	g	DDover	24	h	CIII	(n = 46)	–	4	gevery	6	h	over30	min	II
CI-	33/37(89.2%)II-	26/46	(56.2%)
CI-	8/37	(21%)II-	14/46	(30.4%) Higher	clinicalefficacyachieved	bycontinuousinfusion.	HigherDD	reachedtargetconcentration	forpathogens	withhigher	MIC’s
Li	et	al.	2010
(19)
china
Randomisedcontrol	trial66	patients	withseverepneumonia
CI	(n = 28)	− 4.5	g	every	8	hrsover	8hr	CIII	(n = 31)-	4.5	gevery	8hrs	over30	min	II
CI-	24/32	(75%)II-	17/34	(50%) CI-	not	recordedII-	not	recorded Results	obtainedfrom	the	studysuggest	clinicaladvantages	of	CIcompared	with	IIadministration	inpatientssuffering	withseverepneumonia.
Rose	et	al	2011(35)
USA
Retrospectivecohort	study90	ICU	patients
PI	(n = 54)	–3.375	g	every	8–12	hrs	over	4hrPIII	(n = 36)	− 
PI-	not	recordedII-	not	recorded CI-	not	recordedII-	not	recorded PI	reduced:	(1)days	of	therapyin	ICU,	(2)	timespent	onventilator,	(3)
9II	(n = 36)	− 
3.375	g	every	8–12	hrs	over30	min	II
ventilator,	(3)
length	of	ICU	andhospital	stayand,	(4)mortality.
Ye	et	al.	2011
(20)
china
Randomisedcontrol	trial66	ICU	patients,gram	(–)bacteria
PI	(n = 35)	− 4.5	g	every	8hrsover	a	3	h	PIII	(n = 31)	–	4.5	gevery	8hrs	over30	min	II
PI-	24/35(68.6%)II-	13/31	(41.9%)
PI-	8/35	(22.9%)II-	8/31	(25.8%) Prolongedinfusion	issuperior	totraditionalregimens	andshould	berecommendedas	empiricaltherapy	for	gram(-)	bacteria
Yost	et	al.	2011
(21)
USA
Retrospectivecohort	study270	ICU	patientswith	Pa
PI	(n = 186)	− 3.375	g	every	8hrs	over	4hr	PIII	(n = 84)	-	dosenot	recorded,30	min	II
PI-	171/186(90.3%)II-	67/84	(79.8%)
PI-	18/186(9.7%)II-	17/84	(20.2%)
Pharmacodynamic	dosing	via	PI’sof	piperacillin-tazobactamdemonstratedpositive	outcomecompared	with	II.PRT	need	tofurther	verifyfindings.
Fahmi	et	al.	2012
(22)
Quasiexperimentalstudy61	ICU	patientswith	VAP
PI	(n = 31)	–	3	gevery	8hrs	overa	4	h	PIII	(n = 30)	− 3	gevery	6hr	over30	min	II
PI-	not	recordedII-	not	recorded PI-	not	recordedII-	not	recorded No	significantdifference	inclinical	outcomeof	PI	and	II.Suggestadministrationby	PI	or	IIaccording	to	MICof	organism.
Pereira	et	al.
2012	(23)
portugal
Retrospectivecohort	study346	ICU	patients
CI	(n = 173)	–Majority	18	gDD,	every	8hrII	(n = 173)	–Majority	18	gDD,	30	min	II
CI-	124/173(71.7%)II-	124/173(71.7%)
CI-	49/173(28.3%)II-	49/173(28.3%)
Clinical	efficacyof	piperacillin-tazobactamdosing	wasindependent	ofthe	mode	ofadministration.CI	is	notassociated	witha	decrease	inmortality.
Lee	et	al.	2012
(24)
usa
Retrospectivecohort	study148	ICU	patients
PI	(n = 68)	–3.375	g	every8hrs	over	4hr	PIII	(n = 80)-2.25	g	every	6hrover	30	min	II
PI-	55/68	(81%)II-	50/80	(62%) PI-	13/68(19.1%)II-	30/80	(37.5%)
Results	suggestimproved	30-daymortality	in	ICUpatients	treatedvia	PI	vs	CI.Clinical	benefitsof	PI	at	lowerMIC’s	are	lesssubstantialcompared	withmore	RO.
Waxier	et	al.
2012	(25)
-
Retrospectivecohort	study400	ICU	patients
PI	(n = 200)	-dose	notrecorded,	over4hr	PIII	(n = 200)	-dose	notrecorded,	over30	min	II
PI-	not	recordedII-	not	recorded PI-	not	recordedII-not	recorded PI	patientsreceived	fewerdoses	anddemonstrateddecreasedmorbidity	andmortality;	resultshowever	are	notSS	so	largerprospectivestudies	areneeded.
Lu	et	al.	2013
(26)
china
Randomizedcontrol	trial50	patients	withHAP
PI	(n = 25)	− 4.5	g	every	6hrsover	a	3	h	PIII	(n = 25)	− 4.5	g	every	6hrsover	30	min	II
PI-	22/25	(88%)II-	20/25	(80%) PI-	not	recordedII-	not	recorded PI’s	ofpiperacillin-tazobactam	forgram	negativebacteria	withhigh	MIC	values,like	HAP,	providestable	plasmaconcentrationand	curative
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and	curative
clinical	effect.
Cutro	et	al.	2014
(27)
usa
Retrospectivecohort	study843	patientssuffering	fromsepsis
PI	(n = 662)	–2.25–3.375	gevery	6–12	hover	4	h	PIII	(n = 181)	–2.25–4.5	g	every8–12	h	over30	min	II
PI-	540/662(81.6%)II-	145/181(80.1%)
PI-	72/662(10.9%)II-	25/181(13.8%)
No	significantdifferencebetween	the	twodosing	regimenswas	observed	interms	ofmortality	orclinical	curehowever	patientson	PI	had	ashorter	durationof	therapy.
Jamal	et	al.	2015
(28)
MALAYSIA
Randomisedcontrol	trial16	ICU	patients
CI	(n = 8)	− 2.25	g	LD + 9	gDD	over	24	h	CIII	(n = 8)	–	2.25	gevery	6hr	over30	min	II
CI-	6/8	(75%)II-	6/8	(75%) CI-	0/8	(0%)II-	0/8	(0%) CI	isadvantageous	inthe	presence	ofmore	resistantpathogens	as	itallowsachievement	ofrapid	andconsistentpiperacillin-tazobactamconcentrations.
Abdul-aziz	et	al
2016	(33)
mALAYSIA
Randomisedcontrol	trial85	ICU	patients
CI	(n = 38)	–dose	notrecordedII	(n = 47)	–	dosenot	recorded
CI-	22/38	(58%)II-	15/47	(32%) CI-	7/38	(18.4%)II-	20/47	(42.6) Results	showedthat	CIpiperacillin-tazobactamdemonstratedhigher	clinicalcure	rates	andbetter	PK/PDtargetattainmentcompared	to	II.
schmees	et	al
2016	(31)
usa
Retrospectivecohort	study113	ICU	patients
PI	(n = 61)	–3.375-4.5	gevery	8–12	hII	(n = 52)	–	dosenot	recorded
PI-31/61	(50.8%)II-22/52	(42.3%) PI-9/61	(14.8%)II-11/52	(21.1%) Mortality	ratesand	length	ofhospital	stayweresignificantlylower	in	PIpatients.	PIimproves	patientoutcomes	whilemaintainingpatient	safetyand	decreasingcost.
Cortina	et	al.
2016	(29)SPAIN
Randomisedcontrol	trial78	Patients	withsuspected	Pa
CI	(n = 40)	–	2	gLD + 8	g	DD	over24	h	CIII	(n = 38)	–	4	gevery	8	h	over30	min	II
CI-	20/40	(50%)II-	18/38	(47.4%) CI-	0/40	(0%)II-	1/38	(2.6%) No	SS	differencein	efficacybetween	CI	&	II.Data	indicatesbetterperformance	of	IIthan	CI.	II	curerates	almostdoubled	CI.
Winstead	et	al.
2016	(30)
USA
Retrospectivecohort	study181	patients,gram	(-)	bacteria
PI	(n = 86)	–4.5	g	LD + 3.375	g	every6	h	over	3	h	PIII	(n = 95)	− 4.5	g	every	8hrsover	30	min	II
PI-	not	recordedII-	not	recorded PI-	7/86	(8.1%)II-	6/95	(6.3%) No	SS	differencein	the	primaryoutcome	ofmortality	andlength	ofhospital	stay,however,	30-dayhospital	re-admission	wassignificantlyreduced	in	PIpatients.
BAO	ET	AL	2017
(32)
CHINA
Randomisedcontrol	trial50	patients	withHAP
PI	(n = 25)	–4.5	g	every	6	hover	a	3	h	PIII	(n = 25)	–	4.5	gevery	6	h	over30	min	II
PI-	22/25	(88%)II-	20/25	(80%) PI-	0/25	(0%)II-	0/25	(0%) Dosing	regimenhad	no	impacton	adequacy	oftreatment	andthat	PI	is	aseffective	as	II.	PIis	potentially	a
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is	potentially	a
more	costeffectivealternative	to	II.
Fan	et	al	2017
(34)
CHINA
Prospectivecohort	study367	ICU	patients
PI	(n = 182)	− 4.5	g	every	8–12	h	over	4	h	PIII	(n = 185)	− 4.5	g	every	8–12	h	over	30	minII
PI-	not	recordedII-	not	recorded PI-	21/182(11.5%)II-	29/185(15.6%)
No	significantdifferencebetween	the	twodosing	regimensin	terms	ofmortality	rateand	length	ofhospital	stay
ICU = INTENSIVE	CARE	UNIT;	CI = CONTINUOUS	INFUSION;	II = INTERMITTENT	INFUSION;	PI = PROLONGED	INFUSION;	MIC = MINIMAL	INHIBITION	CONCENTRATION;	LD = LOADING	DOSE;	DD = DAILYDOSE;	VAP = VENTILATOR-ASSOCIATED	PNEUMONIA;	PD = PHARMACODYNAMIC;	CC = CLINICAL	CURE;PA = PSEUDOMONAS	AERUGINOSA;	SS = STATISTICALLY	SIGNIFICANT;	PRT = PROSPECTIVERANDOMISED	TRIALS;	RO = RESISTANT	ORGANISMS;	HAP = HOSPITAL	ACQUIRED	PNEUMONIA
Study	Quality
The	methodological	quality	of	the	included	RCT’s	was	assessed	with	the	Jadad	Scale	(11)	(Table	3)
whereas	the	quality	of	observational	studies	included	were	analysed	using	a	Newcastle-Ottawa	Scale
judgement	(12)	(Table	4).	The	quality	of	the	majority	of	RCT’s	included	was	moderate	to	high.
According	to	the	Jadad	scale,	seven	out	of	ten	RCT’s	(70%)	obtained	a	score	of	three	and	above.	The
studies	by	Ye	(20)	and	Lu	(26)	had	a	score	of	one	and	two	respectively	due	to	retrieval	of	only	the
abstract	(full	text	unavailable).	Rafati	(15)	received	a	score	of	two	as	the	article	did	not	describe
randomisation	method	and	study	was	not	blinded.	All	observational	studies	assessed	using	the
Newcastle	Ottawa	Scale	scored	eight	or	nine	stars	and	recognised	as	being	of	high	quality.
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Table	3
Quality	assessment	of	randomised	control	trials	in	meta-analysis	based	on	the	Jadad	Scale
QUALITY
ASSESSMENT
OF
RCT’S
LAU
(14)
RAFATI
(15)
ROBERT
(17)
LI
(19)
YE
(20)
LU
(26)
JAMAL
(28)
ABDUL
(33)
COTRINA
(29)
BAO	(32)
	 2006 2006 2009 2010 2011 2013 2015 2016 2016 2017
(1)
DESCRIBED	ASRANDOMISED
1 1 1 1 1 1 1 1 1 1
(2)
DESCRIBED	ASDOUBLEBLIND
0 0 0 0 0 0 0 0 1 0
(3)
DESCRIPTION	OFWITHDRAWALS
1 1 1 1 0 1 1 1 1 1
(4)
RANDOMISATIONMETHODDESCRIBED
1 0 1 1 0 0 1 1 1 1
(5)
DOUBLEBLINDINGMETHODDESCRIBED
0 0 0 0 0 0 0 0 1 0
SCORE	(-/5) 3/5 2/5 3/5 3/5 1/5 2/5 3/5 3/5 5/5 3/5
	 	 	 	 	 	 	 	 	 	 	
RCT’S = RANDOMISED	CONTROL	TRIALSRANDOMISATION:
UP	TO	TWO	POINTS	ARE	GIVEN:	(1)	DESCRIBED	AS	RANDOMISED	(YES = 1)	(NO = 0)	AND	(4)	RANDOMISATION
METHOD	DESCRIBED	(YES = 1)	(NO = 0)
DOUBLE	BLINDING:
UP	TO	TWO	POINTS	ARE	GIVEN:	(2)	DESCRIBED	AS	DOUBLE	BLIND	(YES = 1)	(NO = 0)	AND	(5)	DOUBLE	BLINDING
METHOD	DESCRIBED	(YES = 1)	(NO = 0)
REPORTS	OF	WITHDRAWALS	AND	DROPOUTS:
UP	TO	ONE	POINT	IS	GIVEN:	(3)	DESCRIPTION	OF	WITHDRAWALS	(YES = 1)	(NO = 0)
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Table	4
Quality	assessment	of	observational	studies	based	on	the	Newcastle-Ottawa	Scale
STUDY SELECTION COMPARABILITYOU COME SCORE
	 A B C D E F G H 	
GRANT2002	(13)
(p)
* * * * ** * * * 9*
LODISE2007	(16)
(R)
* * * * ** * * * 9*
LORENTE2009	(18)
(R)
* * * * ** * * * 9*
ROSE2011	(35)
(R)
* * * * ** * * * 9*
YOST2011	(21)
(R)
* * * * * * * * 8*
PEREIRA2012	(23)
(R)
* * * * ** * * * 9*
LEE	2012
(24)	(R)
* * * * ** - * * 8*
WAXIER2012	(25)
(R)
* * * * ** - * * 8*
CUTRO2014	(27)
(R)
* * * * * * * * 8*
SCHMEES2016	(31)
(R)
* * * * ** - * * 8*
WINSTEAD	2016
(30)	(R)
* * * * ** - * * 8*
FAN	2017
(34)	(P)
* * * * ** - * * 8*
(P) = PROSPECTIVE	COHORT	STUDY	AND	(R) = RETROSPECTIVE	COHORT	STUDYSELECTION:
A:	REPRESENTATION	OF	THE	EXPOSED	COHORT	(YES	=	*)	(NO=	-),	B:	SELECTION	OF	NON-EXPOSED	COHORT	(YES
=	*)	(NO=	-),	C:	ASCERTAINMENT	OF	EXPOSURE	(YES	=	*)	(NO=	-),	D:	DEMONSTRATION	THAT	OUTCOME	OF
INTEREST	WAS	NOT	PRESENT	AT	START	OF	STUDY	(YES	=	*)	(NO=	-)
COMPARABILITY:
E:	COMPARABILITY	OF	COHORTS	ON	THE	BASIS	OF	THE	DESIGN	OR	ANALYSIS	[CONTROLS	FOR:	AGE,	SEX	AND
MARITAL	STATUS	(YES	=	*)	(NO=	-)	AND	FOR	OTHER	FACTORS	(YES	=	*)	(NO=	-)]
OUTCOME:
F:	ASSESSMENT	OF	OUTCOME	(YES	=	*)	(NO=	-),	G:	WAS	FOLLOW	UP	LONG	ENOUGH	FOR	OUTCOME	TO	OCCUR
(YES	=	*)	(NO=	-)	AND	H:	ADEQUACY	OF	FOLLOW	UP	OF	COHORTS	(YES	=	*)	(NO=	-).
Meta-Analysis	of	Included	Studies
Clinical	Cure
Seventeen	of	the	included	studies	reported	clinical	cure	rates	(Table	1)	(6,13,26–29,31–33,14,15,18–
21,23,24).	Patients	that	received	C/PI	had	a	statistically	significantly	higher	clinical	cure	rate
compared	to	those	who	received	treatment	via	II	(2535	patients;	OR	1.56,	95%	C.I	1.28–1.90,	P = 0
.0001;	Fig.	2).	No	significant	heterogeneity	was	found	among	the	studies	(I2 = 41%,	P = 0.04).	The
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symmetrical	funnel	plot	obtained	indicates	the	absence	of	publication	bias	(Fig.	3).
Despite	methodological	differences	among	selected	studies,	patients	receiving	C/PI	displayed	higher
clinical	cure	rates	compared	with	patients	receiving	II;	overall,	clinical	cure	rate	was	79.62%	and
69.26%	for	C/PI	and	II	respectively.	Pooling	results	from	the	17	studies	that	reported	clinical	cure
showed	that	the	odds	of	clinical	cure	was	higher	in	patients	receiving	C/PI.	The	pooled	OR	shows	that
C/PI	piperacillin-tazobactam	was	1.56	(95%	C.I	1.28–1.90,	P = 0	.0001),	indicating	clinical	cure	rates
are	34%	higher	than	in	II	with	the	true	population	effect	between	72%	and	10.
Mortality
Eighteen	of	the	included	studies	reported	patient	mortality	rates	(Table	1)	(13,14,28–34,36,15–
18,20,21,24,27).	Statistically	significantly	fewer	mortality	rates	were	found	among	patients	receiving
C/PI	compared	with	patients	receiving	conventional	II	(3100	patients;	OR	0.68,	95%	C.I	0.55–0.84,	P = 
0	.0003;	Fig.	4).	No	significant	heterogeneity	was	found	among	the	studies	(I2 = 0%,	P = 0.56).	The
symmetrical	funnel	plot	obtained	indicates	the	low	possibility	of	publication	bias	(Fig.	5).
Results	obtained	from	meta-analysis	suggested	that	C/PI	piperacillin-tazobactam	resulted	in
significantly	lower	mortality	rates.	Overall,	ICU	mortality	rate	was	12.46%	and	18.13%	for	C/PI	and	II
respectively.	Combining	results	from	18	studies	that	reported	mortality,	the	pooled	OR	shows	that
C/PI	piperacillin-tazobactam	was	0.68	(95%	C.I	0.55–0.84),	indicating	lower	mortality	rates	compared
with	conventional	II.	This	was	statistically	significant	(P = 0.0003)	with	the	true	population	effect
between	84%	and	55%.
Microbiological	Cure
Seven	of	the	included	studies	reported	microbiological	cure	rates	(13,14,19,20,23,27,33).	Lau	et	al
(14)	found	no	statistically	significant	difference	between	the	dosing	regimens	however,	higher
microbiological	success	was	seen	in	patients	receiving	II.	In	contrast,	Abdul-Aziz	et	al	(33)	found	C/PI
piperacillin-tazobactam	had	significantly	higher	microbiological	cure	rates	compared	with	II.	Pooling	of
the	outcomes	of	seven	studies	that	reported	microbiological	cure	rates	showed	that	patients	receiving
C/PI	had	significantly	higher	microbiological	success	rates	(920	patients;	OR	1.52,	95%	C.I	1.10–2.11,
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P = 0.01;	Fig.	6).	No	significant	heterogeneity	was	found	among	studies	(I2 = 0%,	P = 0.48).	The
symmetrical	funnel	plot	obtained	demonstrates	the	absence	of	publication	bias	(Fig.	7).
The	pooled	OR	shows	that	C/PI	piperacillin-tazobactam	was	1.52	(95%	C.I	1.10–2.11),	indicating	C/PI
piperacillin-tazobactam	achieved	higher	microbiological	cure	rates	compared	to	conventional	II.
Overall,	microbiological	cure	rates	were	74.83%	and	61.89%	for	C/PI	and	II	respectively.	This	was
statistically	significant	(P = 0.01).
Adverse	Events
Six	of	the	included	studies	reported	adverse	events	(13,14,31–34).	Participants	enrolled	in	three	of
these	studies	observed	adverse	event	(14,31,32).	The	average	occurrence	of	adverse	events	was
13.3%	for	C/PI	and	13.4%	for	II,	respectively.	Participants	in	the	other	three	studies	did	not	experience
adverse	events	(13,33,34).	Data	obtained	from	studies	showed	no	significant	difference	between	the
two	infusion	strategies	(935	patients;	OR	0.85,	95%	C.I	0.50–1.42,	P = 0.53;	Fig.	8).	No	significant
heterogeneity	was	found	among	studies	(I2 = 25%,	P = 0.26).
From	the	23	studies,	six	reported	data	regarding	adverse	events	that	occurred	during	the
administration	of	piperacillin-tazobactam	for	both	dosing	regimens.	Three	studies	reported	that
adverse	events	were	not	observed	(13,33,34)	however,	dosing	and	administrative	errors	arose	in	the
study	by	Grants	et	al	(13)	where	one	patient	was	administered	13.5	g	piperacillin-tazobactam	dose
over	a	30	minute	II	rather	than	a	24-hour	CI.	Lau	et	al’s	(14),	Bao	et	al	(32)	Schmees	et	al	(31)
observed	treatment-related	adverse	events	in	patients	receiving	both	C/PI	and	II;	CI:	16.9%	vs
II:13.6%,	CI:	47.5%	vs	II:53.8%,	CI:	76%	vs	II:92%,	respectively.
Boa	(32)	reported	seriously	adverse	events	in	9	patients	(PI:5	vs	II:4),	including	renal	failure,
Tachycardia	and	confusion.	Cortina	et	al	(29)	reported	that	the	most	common	side	effects
experienced	by	patients	were	gastrointestinal	and	allergic	reactions	but	the	number	of	patients	that
experienced	these	was	not	reported.	The	meta-analysis	demonstrated	that	no	adverse	events	that
are	directly	associated	to	the	dosing	regimens	occurred.	C/PI	resulted	in	a	lower	percentage	of
adverse	events	however,	the	difference	between	the	two	groups	did	not	reach	statistical	significance
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(935	patients;	OR	0.85,	95%	C.I	0.50–1.42,	P = 0.53;	Fig.	8).
Length	of	Hospital	Stay
Fifteen	of	the	included	studies	reported	length	of	hospital	stay	(13,14,31,33–
35,37,15,16,18,23,24,26,29,30).	Pooling	of	studies	showed	that	patients	receiving	C/PI	had	a
significantly	shorter	length	of	hospital	stay	(2101	patients;	OR	-1.27,	95%	C.I	-2.45—0.08,	P = 0.04;
Fig.	9)	The	meta-analysis	suggests	there	is	a	significant	reduction	in	the	length	of	hospital	stay	in
patients	receiving	C/PI	compared	to	those	receiving	II.	Moderate	heterogeneity	among	studies
evaluating	‘length	of	hospital	stay’	(I2 = 65%,	P = 0.0003)	was	observed.	This	is	likely	due	to	clinical
heterogeneity	in	the	design	and	outcomes	of	the	included	studies.
Emergence	of	Resistance
Data	regarding	the	emergence	of	resistance	was	reported	in	four	of	the	included	studies
(13,14,17,18).	Two	resistant	pathogens	were	isolated	in	one	study	(13)	however,	resistant	strains
were	not	isolated	in	three	studies	(14,17,18)	following	the	initiation	of	piperacillin-tazobactam
treatment.	Three	studies	reported	that	no	resistant	pathogen	was	isolated	following	the	initiation	of
piperacillin-tazobactam	treatment.	In	the	study	conducted	by	Grant	et	al	(13),	two	resistant	strains
were	isolated	from	patients	receiving	CI	piperacillin-tazobactam.
Risk	of	Bias
The	majority	of	RCT’s	and	prospective	studies	assessed	were	judged	to	have	a	low	risk	of	bias	for
random	sequence	generation,	allocation	concealment,	incomplete	outcome	data,	selective	reporting
and	other	biases.	However,	evaluations	of	blinding	of	participants	and	personnel	parameter	was
judged	to	have	a	high	or	unclear	risk	of	bias.
4	Discussion
To	the	best	of	our	knowledge,	this	systematic	review	and	meta-analysis	is	the	largest	study	describing	clinical
outcomes	of	severely	ill	patients	treated	with	either	C/PI	or	II	piperacillin-tazobactam.	The	selected	studies
involved	3828	critically	ill	adult	participants	in	total	(C/PI = 2197	and	II = 1631)	from	geographically	diverse
regions.
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It	is	the	first	meta-analysis	that	shows	C/PI	resulted	in	significantly:	(1)	higher	clinical	cure	rates	(2)	lower	of
mortality	rates	(3)	higher	microbiological	success	rates	and	(4)	decreasing	the	length	of	hospital	stay	specifically
in	critically	ill	patients.	In	all	the	studies,	the	primary	outcome	assessed	was	clinical	efficacy.	The	current	study
differs	from	previously	published	systematic	reviews	and	meta-analyses	(4,38–44)	as	it	specifically	focuses	on
use	of	piperacillin-tazobactam	in	critically	ill	ICU	patients.	The	present	systematic	review	and	meta-analysis
identified	a	significant	clinical	cure,	mortality,	microbiological	cure	and	length	of	hospital	stay	benefit	for	C/PI
across	all	included	studies.
In	theory,	C/PI	of	piperacillin-tazobactam	is	a	broadly	recognised	strategy	to	optimize	antibiotic	therapy,	where
concentrations	remain	above	the	MIC	for	a	higher	percentage	of	time.	Studies	have	demonstrated	that	the
amount	of	time	in	which	the	free	or	non-protein	bound	antibiotic	concentration	exceeds	the	MIC	(fT > MIC)	of	the
organism	is	the	best	predictor	of	clinical	and	microbiologic	response	for	β-lactams	(45,46).	However,	data	to
backup	this	developing	practice	have	been	sparse	(42).	Twenty-three	published	studies	comparing	C/PI	and	II	of
piperacillin-tazobactam	fit	the	inclusion	criteria	(Table.2).
Outcomes	of	the	current	study	correlate	and	expand	upon	previously	published	reviews	including	several
analyses	comparing	clinical	efficacy	of	dosing	regimens	for	beta-lactams	generally	(38–41).	These	studies	pointed
towards	a	more	favourable	outcome	of	C/PI	for	improved	clinical	cure	and	resolution	of	illness.	Falagas	et	al	2013
(39)	and	Vardakas	el	al	2018	(40)	reviewed	outcomes	of	C/PI	and	II	beta-lactams.	There	was	a	significant
reduction	in	mortality	rates	among	patients	receiving	C/PI	in	both	studies.	Roberts	et	al	2016	(41)	observed
higher	clinical	rates	and	reduced	mortality	in	C/PI	patients	and	Lal	et	al	2016	(38)	found	C/PI	to	reduce	clinical
failure	rates.
Finding	in	this	study	are	consistent	with	published	reviews	focused	specifically	on	piperacillin-tazobactam	(4,42–
44).	Yusuf	el	at	2014	(4)	reviewed	literature	comparing	the	effectiveness	of	C/PI	and	II	administration	of
piperacillin-tazobactam.	They	documented	C/PI	improved	clinical	cure,	mortality	and	length	of	hospital	stay	in
comparison	to	II.	Yang	et	al	2015/6	(43,44)	observed	similar	beneficial	effects	of	C/PI	in	their	systematic	reviews.
Recently,	Rhodes	et	al	2017	(42)	evaluated	a	wide	range	of	severely	ill	patients,	from	hospitalised	patients	to
critically	ill	patients	admitted	to	ICU.	C/PI	piperacillin-tazobactam	is	associated	with	improved	clinical	outcome
and	significantly	reduced	mortality	rates.
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Several	limitations	of	this	analysis	should	be	noted.	First,	clinical	heterogeneity	was	present	as	selected	studies
comparing	C/PI	and	II	in	terms	of	clinical	outcomes	have	confounding	factors	including	patient	sample	size,	study
settings,	study	design,	quality,	intervention	and	outcomes.	The	benefits	and	outcome	gain	achieved	with	C/PI
administration	in	comparison	to	II	is	difficult	to	quantify	as	studies	selected	show	considerable	heterogeneity	in
terms	of:	(1)	type	of	isolated	bacteria,	(2)	piperacillin-tazobactam	dose,	(3)	MIC	of	pathogen,	(4)	patient	renal
function,	(5)	duration	of	hospital	stay	and	(6)	outcome	definitions.	Second,	information	regarding	monotherapy
and	combination	antibiotic	therapy	were	not	reported	in	the	included	studies.	This	reduces	the	validity	of
conclusions	on	C/PI,	as	agents	used	possess	different	antimicrobial	spectrum,	and	drug-drug	interactions	were
unknown	hence	not	considered.	Third,	assessing	safety	was	challenging	due	to	under-reporting	of	adverse
events.	Higher	serum	concentrations	in	C/PI	patients	over	a	longer	period	could	potentially	result	in	an	increased
number	of	adverse	events.	Fourth,	throughout	this	review,	PI	and	CI	were	combined	and	referred	to	as	C/PI,	thus,
it	is	unclear	which	of	the	two	dosing	strategies	is	most	effective	for	critically	ill	patients.	Fifth,	a	large	number	of
included	studies	were	RCT’s	(10/23;	43.5%)	with	small	sample	size.	Small	sample	size	may	result	in	bias	and	the
probability	of	small	study	effects	contributing	to	the	favourable	outcome	for	C/PI.	However,	meta-analyses
including	small	and	large	studies	did	not	indicate	significant	discrepancies	and	similar	outcomes	were	observed
with	fixed	and	random	effect	models.
5	Conclusion
In	conclusion,	C/PI	of	piperacillin-tazobactam	in	critically	ill	patients	was	associated	with	(1)	higher	clinical	cure
rates	(2)	lower	of	mortality	rates,	(3)	higher	microbiological	success	rates	and,	(4)	a	reduction	in	adverse	events
and	(5)	decreasing	the	length	of	hospital	stay	in	critically	ill	ICU	patients.	There	is	a	significant	level	of	evidence
that	clinical	outcome	in	critically	ill	patients	is	better	in	those	receiving	C/PI.	Therefore,	this	alternative	infusion
strategy	could	be	recommended	in	clinical	practice.
Abbreviations
C.I
Confidence	Interval
CI
Continuous	Infusion
C/PI
Continuous/Prolonged	Infusion
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ICU
Intensive	Care	Unit
II
Intermittent	Infusion
MD
Mean	Difference
MIC
Minimal	Inhibitory	Concentration
OR
Odds	Ratio
PD
Pharmacodynamics
PI
Prolonged	Infusion
PK
Pharmacokinetics
RCT
Randomised	Controlled	Trials
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Figure	1
Flow	diagram	illustrating	the	selection	process	for	included	studies
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Figure	2
Forest	plot	representing	the	odds	ratio	of	clinically	cured	patients	from	the	C/PI	and	II	patients	in
included	studies
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Figure	3
Symmetric	funnel	plot	indicating	the	absence	of	publication	bias	in	terms	of	clinical	cure
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Figure	4
Forest	plot	representing	the	odds	ratio	of	mortality	patients	from	C/PI	and	II	patients	in	included	studies
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Figure	5
Symmetric	funnel	plot	indicating	the	absence	of	publication	bias	in	terms	of	patient	mortality
Figure	6
Forest	plot	representing	the	odds	ratio	of	microbiologically	cured	patients	from	the	C/PI	and	II	patients
in	included	studies
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Figure	7
Symmetric	funnel	plot	indicating	the	absence	of	publication	bias	in	terms	of	microbiological	cure
Figure	8
Forest	plot	representing	the	odds	ratio	of	adverse	events	experienced	by	patients	from	the	C/PI	and	II
groups	in	included	studies
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Figure	9
Forest	plot	representing	the	MD	of	length	of	hospital	stay	in	C/PI	and	II	groups	in	included	studies
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Figure	10
a)	Risk	of	bias	summary	of	included	RCT’s:	displaying	details	about	each	risk	of	bias	item	for	each	trial.
Green	(+)	indicates	‘low	risk’,	red	(-)	indicates	‘high	risk’	and	yellow	(?)	indicates	‘unclear	risk’.	b)	Risk
of	bias	assessment	displaying	judgements	about	each	risk	of	bias	item	presented	as	percentages	across
all	RCT’s
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